7 vs 14 Days of Antibiotics for Bacteremia, Factor XI Inhibition for Atrial Fibrillation, ACEi or ARB Before Elective Surgery, GLP-1 Agonist for HFpEF and Obesity

Following a refreshing break, the hosts dive into critical medical discussions. They explore the BALANCE trial, weighing the effectiveness of seven versus fourteen days of antibiotics for bacteremia, revealing insights on antimicrobial resistance. The conversation shifts to Factor XI inhibitors, highlighting new anticoagulants like abilacimab for atrial fibrillation. Lastly, they discuss GLP-1 agonists, specifically terzepatide, and their promising results in treating heart failure with preserved ejection fraction and obesity.